Use of carbamate compounds for the prevention, alleviation, or treatment of absence seizures or epilepsy exhibiting absence seizures
A carbamate compound effectively suppresses spike-and-wave discharges in epilepsy models, addressing the limitations of current treatments for absence seizures by reducing seizure frequency and duration.
Patent Information
- Application Number
- JP2023061633
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-11-14
- Filing Date
- 2023-04-05
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2038-11-13
AI Technical Summary
Current treatments for absence seizures, such as valproic acid and ethosuximide, are limited in efficacy and can worsen seizures, while other antiepileptic drugs like carbamazepine are contraindicated, necessitating a more effective therapeutic approach.
A therapeutically effective amount of a carbamate compound, such as carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester, or its pharmaceutically acceptable salts, solvates, or hydrates, is administered to prevent or treat absence seizures by suppressing spike-and-wave discharges (SWD) in epilepsy models.
The carbamate compound significantly reduces the frequency and duration of spike-and-wave discharges in GAERS models, demonstrating potential as a more effective treatment for absence seizures.
Smart Images

Figure 0007578747000011 
Figure 0007578747000012 
Figure 0007578747000013
Abstract
Description
[Technical field]
[0001] The present invention relates to a compound represented by the following formula (1): [ka] (In the formula, R 1 , R 2 , A 1 and R 2 (wherein R is as defined herein), or a pharma- ceutically acceptable salt, solvate, or hydrate thereof, for the prophylaxis, alleviation, or treatment of absence seizures or epilepsy exhibiting absence seizures. [Background technology]
[0002] All symptoms caused by the temporary and irregular abnormal excitation of nerve cells as a whole are called seizures. Epilepsy refers to a group of diseases in which chronic seizures occur even in the absence of physical abnormalities that may cause seizures, such as electrolyte imbalance, acid-base abnormalities, uremia, alcohol withdrawal, and severe sleep deprivation. It is known that continuous drug treatment is necessary in the case of two or more seizures.
[0003] Epileptic seizures are classified based on clinical symptoms and electroencephalography (EEG) findings. According to this classification, epileptic seizures are broadly divided into partial seizures and generalized seizures. Partial seizures refer to neuronal hyperexcitability seizures that begin in a part of the cerebral cortex, while generalized seizures refer to seizures that begin in a wide area of both cerebral hemispheres. Types of generalized seizures include generalized tonic-clonic seizures, absence seizures (petit mal seizures), myoclonic seizures, and atonic seizures, while types of partial seizures include simple partial seizures, complex partial seizures, and secondary generalized seizures caused by partial seizures (Source: Korean Epilepsy Society).
[0004] Among these, absence seizures (petit mal) are characterized by the sudden cessation of activity and the patient staring blankly or tilting the head forward for about 5 to 10 seconds. Occasionally, the patient may be observed slightly shaking the eyes or around the mouth. These symptoms tend to occur when breathing in forcefully (Source: Korean Epilepsy Society). The two most characteristic features of absence seizures are the clinical symptoms of impaired consciousness and the electroencephalogram (EEG) showing spike-and-wave discharges (SWD). Types of epilepsy with symptoms of absence seizures include child absence epilepsy, epilepsy with myoclonic absence, juvenile absence epilepsy, and juvenile myoclonic epilepsy.
[0005] Absence seizures can be divided into typical absence and atypical absence. Typical absence seizures usually end within 2 to 10 seconds and rarely last more than 30 seconds. Therefore, the patient, much less others, may not know whether a seizure has occurred. After the seizure, the patient returns to the behavior or situation they were in just before the seizure without realizing that they had had a seizure. Atypical absence seizures include loss of consciousness, staring with wide-open eyes, blinking eyelids, licking lips, biting, or touching fingers. The frequency of these symptoms may decrease around puberty, but most tend to cause grand mal seizures.
[0006] There are limitations to the types of treatment for absence seizures. Valproic acid or ethosuximide are mainly used, and lamotrigine can also be used, but it is known to be less effective (Non-Patent Document 1). However, anti-epileptic drugs such as carbamazepine, vigabatrin, tiagabine, oxcarbazepine, phenytoin, phenobarbital, gabapentin, and pregabalin are prohibited for patients with absence seizures because they may worsen the absence seizures (Non-Patent Documents 2 and 3). Carboxamide dibenzazepine drugs are used to treat partial-onset seizures but are known to exacerbate generalized seizures, especially absence seizures. [Prior art documents] [Non-patent literature]
[0007] [Non-Patent Document 1] Glauser et al. (2010) “Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy”, New England Journal of Medicine, 362 (9): 790-9 [Non-Patent Document 2] "NICE Guidelines" Retrieved November 3, 2014 [Non-Patent Document 3] Knake et al. (August 8, 1999) “Tiagabine-induced absence status in idiopathic generalized epilepsy” European Journal of Epilepsy 8 (5): 314-317 Summary of the Invention [Problem to be solved by the invention]
[0008] The present invention aims to provide a method for preventing, alleviating or treating absence seizures or epilepsy exhibiting absence seizures.
[0009] The present invention also relates to a compound represented by the following formula (1): [ka] (In the formula, R 1 , R 2 , A 1 and R 2 (wherein R is as defined herein), or a pharma- ceutically acceptable salt, solvate or hydrate thereof, for use in the prophylaxis, alleviation or treatment of absence seizures or epilepsy exhibiting absence seizures. [Means for solving the problem]
[0010] The present invention relates to a method for the preparation of a pharmaceutical composition comprising administering to a patient a therapeutically effective amount of a compound represented by the [ka] (In the formula, R 1 and R 2 are independently hydrogen, halogen, C 1 -C 8 Alkyl, haloC 1 -C 8 Alkyl, C 1 -C 8 Thioalkoxy and C 1 -C 8 alkoxy; A 1 and A 2 wherein one of the groups is CH and the other is N.) or a pharma- ceutically acceptable salt, solvate or hydrate thereof, for preventing, alleviating or treating absence seizures or epilepsy exhibiting absence seizures, is provided.
[0011] The present invention also provides a pharmaceutical composition for preventing, alleviating, or treating absence seizures or epilepsy exhibiting absence seizures, comprising a therapeutically effective amount of the carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate, or hydrate thereof, and further comprising one or more pharma- ceutically acceptable carriers.
[0012] Furthermore, the present invention provides a method for preventing, alleviating, or treating absence seizures or epilepsy exhibiting absence seizures, which comprises administering to a subject a therapeutically effective amount of the carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate, or hydrate thereof. The present invention also provides use of the carbamate compound of formula (1) or a pharma- ceutically acceptable salt, solvate, or hydrate thereof for preventing, alleviating, or treating absence seizures or epilepsy exhibiting absence seizures.
[0013] According to one embodiment of the present invention, in the formula (1), R 1 and R 2 are each independently hydrogen, halogen, or C1-C 8 It is selected from the group consisting of alkyl. In one embodiment, halo C 1 -C 8 The alkyl is a perfluoroalkyl.
[0014] According to another embodiment of the present invention, the carbamate compound of formula (1) is represented by the following formula (2): [ka] The carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester is represented by the formula:
[0015] Those skilled in the art of compound synthesis can easily prepare the carbamate compounds of formula (1) and (2) using known compounds or compounds that can be easily prepared from the known compounds. In particular, the method for preparing the compound of formula (1) is described in detail in International Patent Publications WO2006 / 112685A1, WO2010 / 150946A1 and WO2011 / 046380A2, the contents of which are incorporated herein by reference. The compound of formula (1) can be chemically synthesized according to any of the methods described in the above documents, but these methods are merely examples, and the order of unit operations may be selectively changed as necessary. Therefore, the above methods are not intended to limit the scope of the present invention.
[0016] The carbamate compounds of formula (1) can be used to prevent, alleviate or treat absence seizures or epilepsy exhibiting absence seizures.
[0017] According to one embodiment of the present invention, the absence seizures are largely divided into typical absence seizures and atypical absence seizures. In the case of typical absence seizures, the seizures usually end within 2 to 10 seconds and rarely last more than 30 seconds. Therefore, the patient himself, much less others, may not know whether the patient has had a seizure. After the seizure, the patient returns to the behavior or situation he or she was in just before the seizure without realizing that the seizure had occurred. Atypical absence seizures include loss of consciousness, staring with wide-open eyes, blinking eyelids, licking lips, biting, or touching fingers. The frequency of these symptoms may decrease around puberty, but most tend to cause grand mal seizures.
[0018] According to one embodiment of the present invention, epilepsy exhibiting absence seizures may be one or more selected from childhood absence epilepsy, myoclonic absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, Jeavons syndrome (eyelid myoclonia with absences), genetic generalized epilepsy with phantom absences, and Lennox-Gastaut syndrome.
[0019] According to one embodiment of the present invention, the absence seizures may be typical absence seizures or atypical absence seizures, including all seizures with spike-and-wave discharges (SWD) as an EEG feature. The carbamate compounds of formula (1) can be applied to absence seizures or epilepsy exhibiting absence seizures due to their ability to suppress spike-and-wave discharges (SWD).
[0020] The efficacy of the carbamate compound of formula (1) against absence seizures or epilepsy showing absence seizures can be confirmed using known models.For example, GAERS (Genetic Absence Epilepsy Rat from Strasbourg) model is a kind of rat that shows spontaneous spike-and-wave discharges (SWD) and behavior of absence seizures due to genetic characteristics, and is used as a means to verify the efficacy of therapeutic agents for absence seizures (Depaulis et al., The genetic absence epilepsy rat from Strasbourg as a model to decipher the neuronal and network mechanisms of generalized idiopathic epilepsies. J Neurosci Methods, 2016 Feb 15;260:159-74).
[0021] In rat models of this disease, SWDs are characteristically observed via cortical electroencephalography (EEG), lasting approximately 17-25 seconds each and occurring approximately 45-60 times per hour, and are associated with pauses in activity that are behaviorally characteristic of absence seizures.It is known that SWD in GAERS model rats can be suppressed by valproate, ethosuximide, etc., just like in human patients, and many drugs have no inhibitory effect, or some drugs are known to worsen SWD (Dedeurwaerdere et al., Fluctuating and constant valproate administration gives equivalent seizure control in rats with genetic and acquired epilepsy. Seizure. 2011 Jan;20(1):72-9; Nehlig et al., Cerebral energy metabolism in rats with genetic absence epilepsy is not correlated with the pharmacological increase or suppression of spike-wave discharges. Brain Res. 1993 Jul 30;618(1):1-8; Wallengren et al., Aggravation of absence seizures by carbamazepine in a genetic rat model does not induce neuronal c-Fos activation. Clin Neuropharmacol. 2005 Mar-Apr;28(2):60-5; Gurbanova et al., Effect of systemic and intracortical administration of phenytoin in two genetic models of absence epilepsy. Br J Pharmacol. 2006 Aug;148(8):1076-82; Vartanian et al., Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 2006 Mar;68(3):189-205).
[0022] Therefore, this disease model is considered to be a useful model for predicting effects on absence seizures (Klitgaard et al., Use of epileptic animals for adverse effect testing. Epilepsy Res. 2002 Jun;50(1-2):55-65; van Luijtelaar EL, Drinkenburg WH, van Rijn CM, Coenen AM. Rat models of genetic absence epilepsy: what do EEG spike-wave discharges tell us about drug effects? Methods Find Exp Clin Pharmacol. 2002;24 Suppl D:65-70).
[0023] The dosage of the carbamate compound of formula (1) for the prevention, alleviation or treatment of the disease may typically vary depending on the severity of the disease, the body weight and metabolic state of the subject to be treated. The "therapeutically effective amount" for an individual patient means an amount of active compound sufficient to achieve the pharmacological effect, i.e., the therapeutic effect as described above. The therapeutically effective amount of the compound of formula (1) is 50-500 mg, 50-400 mg, 50-300 mg, 100-400 mg, 100-300 mg, 50-200 mg, or 100-200 mg in free form, based on a single daily administration to humans.
[0024] The compounds of the present invention can be administered by any conventional method used for administering therapeutic agents, including oral, parenteral, intravenous, intramuscular, subcutaneous or rectal administration. A medicament or pharmaceutical composition according to one embodiment of the present invention can comprise a therapeutically effective amount of a compound selected from the group consisting of the carbamate compounds of the present invention, their pharma- ceutically acceptable salts, solvates, hydrates, and combinations thereof.
[0025] Pharmaceutically acceptable salts of the carbamate compounds of formula (1) include, for example, independently, acetate, benzenesulfonate, benzoate, bitartrate, calcium acetate, camsylate, carbonate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycoloylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydrogencarbonate, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methyl nitrate, methyl sulfate, methyl sulphate ... These include phosphate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate / diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate or hemi-succinate, sulfate or hemi-sulfate, tannate, tartrate, oxalate or hemi-tartrate, theoclate, triethiodide, benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, ammonium, tetramethylammonium, calcium, lithium, magnesium, potassium, sodium and zinc.
[0026] The medicament or pharmaceutical composition according to one embodiment of the present invention can be administered orally or parenterally. Parenteral administration can be by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intradermal administration, topical administration, intranasal administration, intravaginal administration, pulmonary administration, and rectal administration. For oral administration, the pharmaceutical composition according to one embodiment of the present invention can be formulated as a plain tablet (uncoated tablet) or such that the active agent is coated or protected from degradation in the stomach. The composition can also be administered by any device that allows the active agent to be transferred to the target cells. The route of administration will vary depending on the general condition and age of the subject to be treated, the nature of the condition to be treated, and the active ingredient selected.
[0027] The suitable dosage of the medicament or pharmaceutical composition according to one embodiment of the present invention varies depending on factors such as the formulation method, administration method, age, weight, sex, pathological condition, diet, administration time, administration route, excretion rate and reaction sensitivity of the patient, and a doctor of ordinary skill can easily determine and prescribe an effective dosage for the desired treatment or prevention. The pharmaceutical composition according to one embodiment can be administered in one or more doses, for example, 1 to 4 times per day. The pharmaceutical composition according to one embodiment can contain 50 to 500 mg, 50 to 400 mg, 50 to 300 mg, 100 to 400 mg, 100 to 300 mg, 50 to 200 mg, or 100 to 200 mg of the compound of formula (1) based on the free form.
[0028] The medicament or pharmaceutical composition according to one embodiment of the present invention can be prepared in unit dose form or in a multi-dose container by formulating it using pharma- ceutically acceptable carriers and / or excipients according to a method that can be easily performed by a person skilled in the art. The formulation may be in the form of a solution, suspension or emulsion in an oily or aqueous medium, an extract, a powder, a granule, a tablet or a capsule, and may additionally contain a dispersing agent or a stabilizing agent. The pharmaceutical composition may also be administered in the form of a suppository, a spray, an ointment, a cream, a gel, an inhalant or a skin patch. The pharmaceutical composition may also be prepared for mammalian administration, more preferably for human administration.
[0029] The pharma- ceutically acceptable carrier may be solid or liquid and may be one or more selected from excipients, antioxidants, buffers, bacteriostatic agents, dispersants, adsorbents, surfactants, binders, preservatives, disintegrants, sweeteners, flavorings, lubricants, release regulators, wetting agents, stabilizers, suspending agents, and lubricants.Furthermore, the pharma-ceutically acceptable carrier may be selected from physiological saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and mixtures thereof.
[0030] In one embodiment, suitable fillers include, but are not limited to, sugars (e.g., dextrose, sucrose, maltose, and lactose), starches (e.g., corn starch), sugar alcohols (e.g., mannitol, sorbitol, maltitol, erythritol, and xylitol), starch hydrolysates (e.g., dextrins and maltodextrins), cellulose or cellulose derivatives (e.g., microcrystalline cellulose), or mixtures thereof.
[0031] In one embodiment, suitable binders include, but are not limited to, povidone, copovidone, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, gelatin, gums, sucrose, starch, or mixtures thereof. In one embodiment, suitable preservatives include, but are not limited to, benzoic acid, sodium benzoate, benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, chlorbutol, gallate, hydroxybenzoate, EDTA, or mixtures thereof.
[0032] In one embodiment, suitable disintegrants include, but are not limited to, sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, starch, microcrystalline cellulose, or mixtures thereof. In one embodiment, suitable sweetening agents include, but are not limited to, sucralose, saccharin, sodium or potassium or calcium saccharin, acesulfame potassium or sodium cyclamate, mannitol, fructose, sucrose, maltose, or mixtures thereof.
[0033] In one embodiment, suitable lubricants include, but are not limited to, silica, colloidal silicon dioxide, talc, and the like. In one embodiment, suitable lubricants include, but are not limited to, long chain fatty acids and their salts, such as magnesium stearate and stearic acid, talc, glyceride waxes, or mixtures thereof.
[0034] As used herein, the terms "prevent," "preventing," and "prevention" refer to reducing or eliminating the chance of acquiring a disease. As used herein, the terms "ameliorate," "alleviating," and "alleviation" refer to the complete or partial alleviation of a disease and / or its associated symptoms. As used herein, the terms "treat", "treating" and "treatment" refer to the total or partial elimination of a disease and / or its associated symptoms.
[0035] The term "subject" as used herein means an animal, preferably a mammal (e.g., primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, etc.), most preferably a human, who is the subject of treatment, observation or experiment. As used herein, the term "therapeutically effective amount" refers to an amount of an active compound or pharmaceutical formulation that induces a biological or medical response in a system, animal or human, including alleviating the symptoms of the disease or disorder being treated, as determined by a researcher, veterinarian, physician (physician) or other clinician.
[0036] As used herein, the term "composition" includes a product containing the specified ingredients in the specified amounts, and any product that is produced directly or indirectly from a combination of the specified ingredients in the specified amounts. Effect of the Invention
[0037] The medicament and pharmaceutical composition according to the present invention can effectively treat and prevent absence seizures and epilepsy exhibiting absence seizures. [Brief description of the drawings]
[0038] [Figure 1]FIG. 1 shows the results of electroencephalography (EEG) measurements observed in baseline conditions of the GAERS model used in the examples, demonstrating the occurrence of spontaneous SWD.
[0039] [Diagram 2] This figure shows the results of analyzing the effect of valproate, used as a positive control, on the number of SWDs generated through electroencephalography (EEG) analysis in the GAERS model, and the effectiveness was analyzed at two doses, 150 mg / kg and 200 mg / kg. The number of SWDs during the 20-minute baseline period immediately before drug administration and the number of SWDs over a total of 80 minutes from 10 to 90 minutes after drug administration are shown.
[0040] [Diagram 3] 1 shows the results of EEG analysis of the effect of the test compound on the occurrence of SWDs generated by the GAERS model, and the efficacy was analyzed at four doses of 5, 10, 20, and 30 mg / kg. The number of SWDs during the 20-minute baseline period immediately before administration of the test compound and the number of SWDs during a total of 80 minutes from 10 to 90 minutes after administration of the test compound are shown.
[0041] [Figure 4] FIG. 1 shows the number of SWDs occurring over a total of 60 minutes from 10 to 70 minutes after administration of a drug or test compound, and the difference in effect between the vehicle-administered group, the test compound-administered group, and the valproate-administered group can be confirmed.
[0042] [Diagram 5] Figure 1 shows the effect of valproate, used as a positive control, on the cumulative duration of SWDs generated by the GAERS model, analyzed over time via EEG analysis, where the efficacy was analyzed at two doses, 150 mg / kg and 200 mg / kg. The cumulative duration of SWDs during the 20-minute baseline period immediately prior to drug administration, and the cumulative duration of SWDs during the 20-minute interval from 10 to 90 minutes after drug administration are displayed.
[0043] [Figure 6] 1 shows the effect of the test compound on the cumulative duration of SWDs generated in the GAERS model analyzed over time through EEG analysis, and the efficacy was analyzed at four doses, 5, 10, 20, and 30 mg / kg. The cumulative duration of SWDs in the baseline period of 20 minutes immediately before administration of the test compound and the cumulative duration of SWDs in 20-minute intervals from 10 to 90 minutes after administration of the test compound are shown.
[0044] [Figure 7] This figure shows the cumulative duration of SWD in 20-minute intervals for a total of 60 minutes from 10 to 70 minutes after administration of a drug or test compound, and enables the difference in effect between the vehicle-administered group, the test compound-administered group, and the valproate-administered group to be confirmed. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0045] The present invention will now be described in further detail with reference to the following examples, which are intended, however, only to illustrate one or more embodiments and are not intended to limit the scope of the invention.
[0046] Production Example: Production of carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester Carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester (test compound) was prepared according to the method described in Preparation 50 of International Publication No. WO2010 / 150946.
[0047] Example: Efficacy testing of prevention and treatment of absence seizures using the GAERS (Genetic Absence Epilepsy Rat from Strasbourg) model GAERS model is a rat species that shows spontaneous SWD due to genetic influence. GAERS model has typical behavioral, electrophysiological and pharmacological characteristics of absence seizures, and thus has been used as a disease model of absence seizures for about 20 years (Depaulis et al., The genetic absence epilepsy rat from Strasbourg as a model to decipher the neuronal and network mechanisms of generalized idiopathic epilepsies. J Neurosci Methods. 2016 Feb 15;260:159-74).
[0048] Experimental animals Twelve 5-week-old GAERS model rats were obtained from the Grenoble Institue of Neurosciences, France. After acquisition, the rats were housed at a temperature of 21 ± 2°C under controlled light conditions (lights on from 8:00 a.m. to 8:00 p.m.) with free access to food and water, and maintained in this condition for 2 months prior to surgery.
[0049] Electrode implantation for EEG measurements Twelve 3-month-old GAERS rats were implanted with EEG electrodes. Stereotaxic implantation was performed under isoflurane (2% concentration in oxygen) anesthesia. The rats were fixed in a stereotaxic frame and the surgery was performed while monitoring their body temperature. Ophthalmic gel was used to prevent the cornea from drying out. After cutting the hair at the incision site, it was disinfected with povidone, and after incision, four holes were made using a drill at the positions of the frontal and parietal cortices of both hemispheres of the open skull. Monopolar electrodes were placed in these holes and connected to a female connector fixed to the skull for EEG recording. The incision site was then sutured. After surgery, buprenorphine was injected subcutaneously at a dose of 0.1 mg / kg, the anesthetic agent was removed, and the rats were observed until they regained consciousness. The rats were then placed in a cage for one week for recovery.
[0050] Selection of animals for drug efficacy testing One week after electrode implantation, a 1-hour preliminary EEG measurement was performed on all 12 animals, and 10 animals were selected that showed a sufficient signal-to-noise ratio suitable for detecting the occurrence of SWD.
[0051] Drug administration The test compound and the positive control drug were prepared immediately before administration. The carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester prepared in the above Preparation Example was dissolved in 30% (volume / volume) PEG300 (81164-14, Sigma-Aldrich), and the positive control valproate (P4543, Sigma-Aldrich) was dissolved in 0.9% sterile saline (Cooper, France). Both drugs were administered intraperitoneally at a dose of 5 mL / kg. 30% PEG300 was used for vehicle administration as a negative control.
[0052] The study was conducted in a cross-over fashion, with a minimum of 71 hours between doses to allow for drug washout. The following conditions were implemented in the first phase of the study: - Vehicle (30% PEG300) -Valproate 200mg / kg - Test compound 5mg / kg - Test compound 10mg / kg - Test compound 20mg / kg The second phase of testing was carried out under the following conditions: -Valproate 150mg / kg - Test compound 30mg / kg
[0053] EEG recording For EEG recording, 10 GAERS rats were placed in a recording chamber and connected to wires to record EEG. After a 1-h habituation step, EEG recordings were performed on freely moving animals. As a baseline phase, recordings were performed 20 min before drug administration and 90 min after drug administration using System Plus Evolution (Micromed). During recordings, animals were kept in a quiet, awake state.
[0054] EEG data analysis SWDs were analyzed using recorded EEG data, and all data analyses were performed in a blinded manner. SWDs were analyzed for a 20-minute baseline phase and a total of 80-minute period from 10 to 90 minutes after drug administration. The 80 minutes were divided into 20-minute intervals and analyzed for the number of SWD occurrences and the accumulated SWD duration (SWD cumulative duration).
[0055] statistical analysis Results are expressed as mean ± SEM and statistical analysis was performed using Prism (GraphPad). Two-way ANOVA was used to analyze the number of SWDs and cumulative SWD duration over time. Bonferroni pairwise comparisons were used to compare with baseline period, with vehicle-treated negative control, and with valproate-treated positive control. For the total effect at 1 hour after drug administration, one-way ANOVA was used for repeated measures and Bonferroni pairwise comparisons were used to compare with vehicle-treated negative control and with valproate-treated positive control. Statistical significance was defined as p<0.05.
[0056] Test results Of the 10 GAERS rats used for EEG recordings, one had a low number of SWDs obtained at baseline and was therefore inappropriate for analysis, and the data from that single rat were excluded from the final analysis.
[0057] 1) Effect of test compounds on the occurrence of SWD The results of a two-way analysis of variance for the measurements in 20-minute intervals are as follows: The vehicle-treated group, which served as a negative control, showed no differences compared to baseline at any time point. In the positive control group, valproate administration reduced the number of SWDs. The 150mg / kg group showed a statistically significant reduction in the number of SWDs in the 10-30 and 30-50 minute intervals after administration compared to the vehicle group. Furthermore, the 200mg / kg group showed a significant reduction in the number of SWDs in the entire time interval after administration (10-90 minutes) compared to the negative control. The test compound groups at doses of 10, 20, and 30 mg / kg showed a significant reduction in the number of SWDs compared to the vehicle group. The 10 mg / kg dose showed significance in the 30-50 minute interval, the 20 mg / kg dose showed significance in the 30-90 minute interval, and the 30 mg / kg dose showed significance throughout the entire interval. Regarding the duration of efficacy, the test compound showed a longer duration than valproate as a positive control.
[0058] Regarding the total effect 1 hour after drug administration, the results of one-way ANOVA showed that the test compound doses of 20 and 30 mg / kg showed a significant reduction in the number of SWD occurrences compared to the vehicle dose group, and showed a similar effect to the valproate doses of 150 and 200 mg / kg.
[0059] 2) Effect of test compounds on cumulative duration of SWD The results of a two-way analysis of variance for the cumulative SWD duration for each 20-minute unit interval are as follows: The vehicle-treated group, which served as a negative control, showed no differences compared to baseline at any time point. The positive control group, administered valproate, showed a reduction in cumulative duration of SWD due to administration of valproate. The 150mg / kg group showed a significant reduction in the 10-30, 30-50, and 50-70 minute intervals after administration, and the 200mg / kg group showed a significant reduction compared to the negative control in all time intervals after administration (10-90 minutes). The test compound groups at doses of 10, 20, and 30 mg / kg showed a significant decrease in the cumulative duration of SWD compared to the vehicle group. The 10 mg / kg dose showed a significant decrease in the 30-50 and 50-70 minute intervals after administration, the 20 mg / kg dose showed a significant decrease in the 30-90 minute interval, and the 30 mg / kg dose showed a significant decrease in the entire interval after administration. Regarding the duration of efficacy, the test compound showed a longer duration than valproate as a positive control.
[0060] Regarding the total effect 1 hour after drug administration, the results of one-way ANOVA showed that the test compound groups at 20 and 30 mg / kg doses significantly reduced the SWD cumulative duration compared to the vehicle group, and showed a similar effect to the valproate groups at 150 and 200 mg / kg doses.
Claims
1. A therapeutically effective amount of the following formula (1) [Formula 1] (In the formula, R 1 and R 2 are each independently hydrogen, halogen, or C 1 -C 8 Alkyl, haloC 1 -C 8 Alkyl, C 1 -C 8 Thioalkoxy and C 1 -C 8 alkoxy; A 1 and A 2 One of them is CH and the other is N.) A pharmaceutical composition for preventing, alleviating or treating epilepsy exhibiting absence seizures, comprising a carbamate compound represented by the following formula (I): The epilepsy exhibiting absence seizures is selected from the group consisting of childhood absence epilepsy, myoclonic absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, Jeavons syndrome (eyelid myoclonia with absence), and hereditary generalized epilepsy with phantom absence.
2. R 1 and R 2 are each independently hydrogen, halogen, or C 1 -C 8 The pharmaceutical composition according to claim 1, characterized in that it is selected from the group consisting of alkyl.
3. The carbamate compound of formula (1) is represented by the following formula (2): [Case 2] The pharmaceutical composition according to claim 1, characterized in that it is carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester represented by the formula:
4. The pharmaceutical composition according to any one of claims 1 to 3, which is prepared for oral or parenteral administration.
5. The pharmaceutical composition according to claim 4, wherein the parenteral administration is intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intradermal administration, topical administration, intranasal administration, intravaginal administration, intrapulmonary administration, or intrarectal administration.
6. The pharmaceutical composition according to any one of claims 1 to 3, characterized in that the therapeutically effective amount of the carbamate compound of formula (1) is 50 mg to 500 mg, based on a once-daily administration in free form.
7. A therapeutically effective amount of the following formula (1) [C3] (In the formula, R 1 and R 2 are each independently hydrogen, halogen, or C 1 -C 8 Alkyl, haloC 1 -C 8 Alkyl, C 1 -C 8 Thioalkoxy and C 1 -C 8 alkoxy; A 1 and A 2 One of them is CH and the other is N.) or a pharma- ceutically acceptable salt, solvate or hydrate thereof, further comprising one or more pharma- ceutically acceptable carriers. A pharmaceutical composition for preventing, alleviating or treating epilepsy exhibiting absence seizures, comprising: A pharmaceutical composition, characterized in that the epilepsy exhibiting absence seizures is selected from the group consisting of childhood absence epilepsy, myoclonic absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, Jeavons syndrome (eyelid myoclonia with absence seizures), and hereditary generalized epilepsy with phantom absence seizures.
8. R 1 and R 2 are each independently hydrogen, halogen, or C 1 -C 8 The pharmaceutical composition according to claim 7, characterized in that it is selected from the group consisting of alkyl.
9. The carbamate compound of formula (1) is represented by the following formula (2): [C4] 8. The pharmaceutical composition according to claim 7, wherein the carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester is represented by the formula:
10. The pharmaceutical composition according to any one of claims 7 to 9, which is prepared for oral or parenteral administration.
11. 11. The pharmaceutical composition of claim 10, wherein the parenteral administration is intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intradermal administration, topical administration, intranasal administration, intravaginal administration, intrapulmonary administration, or rectal administration.
12. The pharmaceutical composition according to any one of claims 7 to 9, characterized in that the therapeutically effective amount of the carbamate compound of formula (1) is 50 mg to 500 mg, based on a single daily administration in free form.
13. The following formula (1) [C5] (In the formula, R 1 and R 2 are each independently hydrogen, halogen, or C 1 -C 8 Alkyl, haloC 1 -C 8 Alkyl, C 1 -C 8 Thioalkoxy and C 1 -C 8 alkoxy; A 1 and A 2 One of them is CH and the other is N.) or a pharma- ceutically acceptable salt, solvate or hydrate thereof for the manufacture of a medicament for the prevention, alleviation or treatment of epilepsy exhibiting absence seizures, comprising: The epilepsy exhibiting absence seizures is selected from the group consisting of childhood absence epilepsy, myoclonic absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, Jeavons syndrome (eyelid myoclonia with absence), and hereditary generalized epilepsy with phantom absence.
14. R 1 and R 2 are each independently hydrogen, halogen, or C 1 -C 8 14. The use according to claim 13, characterized in that it is selected from the group consisting of alkyl.
15. The carbamate compound of formula (1) is represented by the following formula (2): [C6] The use according to claim 13, characterized in that the carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester is represented by the formula:
16. The use according to any one of claims 13 to 15, wherein the medicament is prepared for oral or parenteral administration.
17. 17. The use according to claim 16, wherein the parenteral administration is intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intradermal administration, topical administration, intranasal administration, intravaginal administration, intrapulmonary administration, or rectal administration.
18. The use according to any one of claims 13 to 15, characterized in that the therapeutically effective amount of the carbamate compound of formula (1) is between 50 mg and 500 mg, based on a single daily administration in free form.
Citation Information
Patent Citations
Neurotherapeutic azole compounds
JP2008538557A
